Ophthalmology Value-based Care

Advancing Retina Care with Innovation and Insight

Supporting Ophthalmologists in Delivering Exceptional Outcomes at Reduced Costs

Schedule a Meeting
Z

Improved Clinical Outcomes

Z

Significant Cost Savings

Z

Aligned Provider Incentives

OMI Retina Care

Solving Critical Pain Points to Support Ophthalmologists

Anti-VEGF therapies, frequently used in retina care, represent one of the largest expenditures in outpatient drug spending. Despite equally effective and more affordable options being available, costly treatments often dominate, creating financial stress for providers, payers, and patients.

Provider Partners

Average Injections Annually

Average Annual Patient Liability Savings

%

Visual Acuity Preservation

Savings

Revolutionizing Retina Care with Data-Driven Insights

OMI’s tailored retina program focuses on critical conditions, equipping providers with data and tools to deliver high-quality, cost-effective care. Covered conditions include:

wetAMD

Exudative Age-Related Macular Degeneration

CRVO

Central Retinal Vein Occlusion with Macular Edema

PDR/NPDR

Proliferative and Non-Proliferative Diabetic Retinopathy

BRVO

Branch Retinal Vein Occlusion with Macular Edema

DME

Diabetic Macular Edema

Learn More About Our Retina Solutions

Leveraging OMI PULSE for Smarter Decisions

OMI’s PULSE platform integrates seamlessly into existing clinical workflows, enabling ophthalmologists to make well-informed treatment decisions while improving both cost efficiency and patient outcomes.

How it Works

Identifies patients eligible for optimized treatments

Collects clinical-based outcomes

Offers real-time tracking and performance reporting

Eliminates administrative burdens for providers and payers

Discover OMI PULSE

Retina Program Performance

  • N

    Scale

    OMI has partnered with over 250 Ophthalmologists on the East Coast for its Value-Based Care program with multiple payers which saves partners more than $5M annually.
  • N

    Outcomes-Focus

    ⁠OMI demonstrates, in real-time at the point of care through OMI’s cloud based portal, that > 94% of patients treated with Anti-VEGF maintain visual acuity from visit-to-visit across more than thirty thousand outcomes collected – no different than patients treated with other medications
  • N

    Benefits to Patients

    Patients saved an average of ~$2,190 for Anti-VEGF compared to other medication choices (annual average of 6 injections) through reduction of cost-share.
  • N

    Speed to Savings

    Increased utilization of Value-Based pathway by 8x from historical period within first 12 months, resulting in a net decrease in cost of over $650/injection, after previous attempts between Health Plan and Provider groups had been unsuccessful.
  • N

    Superiority to Alternatives

    Even after distribution to OMI/Provider, Payer Clients saved 7x more with the OMI Shared Savings Approach (Incentivizing the providers, outcomes-focused, protecting practice economics) than with alternative approaches such as Step Therapy/Prior Authorization. Additionally, both payer & provider clients experience a reduced administrative burden in the OMI model compared to alternatives, while creating stronger collaborative relationships.